ALK and Merck Co’s grass allergy tablet finally reaches FDA committee

The US Food and Drug Administration Allergenic Products Advisory Committee will review US pharma giant Merck & Co’s Biologic License Application (BLA) for the investigational grass sublingual allergy immunotherapy (AIT) tablet on Thursday.

Denmark-based allergy specialist ALK Abello (ALKB: DC) became the first pharma victim of the US government shutdown in October when the meeting for its tablet, under development with Merck, its partner for North America, was delayed.